SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Has Average Price Target of $12.00

SAB Biotherapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is moderately positive: Nine of 11 analysts rate SAB Biotherapeutics a Buy, while one rates it Hold and one Sell; the average one-year price target is $12.
  • The company reported a quarterly loss of $0.24 per share, beating the consensus estimate of a $0.27 loss. Analysts expect a loss of $1.13 per share for the current fiscal year.
  • Institutional investors own 7.82% of the stock, and Perceptive Advisors increased its holdings by 700.8% in the first quarter. Shares opened at $3.20, within a 52-week range of $2.44 to $5.15.
  • Five stocks we like better than SAB Biotherapeutics.

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $12.00.

Several equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of SAB Biotherapeutics from a "strong sell" rating to a "sell" rating in a research note on Monday, August 10th. Weiss Ratings upgraded shares of SAB Biotherapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, September 17th.

Read Our Latest Analysis on SAB Biotherapeutics

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC boosted its holdings in shares of SAB Biotherapeutics by 700.8% during the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company's stock worth $24,634,000 after purchasing an additional 5,628,533 shares during the last quarter. Seven Fleet Capital Management LP increased its holdings in shares of SAB Biotherapeutics by 47.2% in the second quarter. Seven Fleet Capital Management LP now owns 736,077 shares of the company's stock valued at $2,871,000 after purchasing an additional 236,077 shares during the last quarter. Affinity Asset Advisors LLC acquired a new stake in shares of SAB Biotherapeutics in the first quarter valued at approximately $2,202,000. Monashee Investment Management LLC acquired a new stake in shares of SAB Biotherapeutics in the first quarter valued at approximately $1,915,000. Finally, DV Trading LLC purchased a new position in SAB Biotherapeutics during the first quarter worth approximately $1,532,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Stock Up 8.5%

NASDAQ SABS opened at $3.20 on Thursday. The business has a fifty day moving average price of $3.09 and a 200 day moving average price of $3.62. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.28 and a current ratio of 7.28. The company has a market cap of $288.29 million, a P/E ratio of -2.41 and a beta of 0.67. SAB Biotherapeutics has a one year low of $2.44 and a one year high of $5.15.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.03. Research analysts anticipate that SAB Biotherapeutics will post -1.13 EPS for the current fiscal year.

SAB Biotherapeutics Company Profile

(Get Free Report)

SAB Biotherapeutics is a biotechnology company developing antibody-based medicines for autoimmune and infectious diseases. Its platform uses genetically engineered cattle to produce fully human polyclonal antibodies, which the company evaluates as potential treatments. The company's pipeline has included SAB-142, an investigational therapy being developed for type 1 diabetes. Earlier programs included antibody candidates targeting infectious diseases, such as influenza and COVID-19. SAB Biotherapeutics was founded in 2014 and is based in Sioux Falls, South Dakota.

Further Reading

Analyst Recommendations for SAB Biotherapeutics (NASDAQ:SABS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SAB Biotherapeutics Right Now?

Before you consider SAB Biotherapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SAB Biotherapeutics wasn't on the list.

While SAB Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines